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Recent reports suggest that two ATM gene mutations, 7271T4G and IVS10-6T4G, are associated with a high risk of breast cancer
among multiple-case families. To assess the importance of these two mutations in another ‘high-risk’ group, young women (under age
51) with multiple primaries, we screened a large population-based series of young women with bilateral breast cancer and compared
the frequency of these mutations among similar women diagnosed with unilateral breast cancer. The 1149 women included were
enrolled in an ongoing population-based case–control study of the genetic factors that contribute to bilateral breast cancer; they
were not selected on the basis of family history of cancer. Screening for 7271T4G and IVS10-6T4G ATM gene mutations was
conducted using DHPLC followed by direct sequencing. The 7271T4G mutation was detected in one out of 638 (0.2%) women
with unilateral breast cancer and in none of the bilateral cases, and the IVS10-6T4G mutation in one out of 511 (0.2%) bilateral and
in eight out of 638 (1.3%) unilateral breast cancer cases. Carriers of either mutation were not limited to women with a family history.
Given the likelihood that young women with bilateral breast cancer have a genetic predisposition, the observed mutation distribution
is contrary to that expected if these two mutations were to play an important role in breast carcinogenesis among individuals at
high risk.
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ATM (for ataxia-telangiectasia (A-T) mutated), a gene whose
product plays a critical role in signalling and responding to the
presence of DNA double-strand breaks, is mutated in the
autosomal recessive disorder A-T. The incidence of breast cancer
among heterozygous carriers in A-T families, along with the
known biochemical interactions between the products of the ATM
and BRCA1 genes, has suggested a role for ATM in breast cancer
risk. The recent study by Chenevix-Trench et al (2002) reported a
greatly elevated risk of breast cancer among five members from
multiple-case breast cancer families, who were heterozygous
for ATM gene mutations, 7271T4G or IVS10-6T4G. The
estimated combined penetrance of the two mutations was
60% (32–90%) to age 70 years. This is equivalent to a relative
risk (RR) of 15.7 (95% confidence interval (CI)¼6.4–38.0)
compared to the general population. These findings are
consistent with two earlier studies: one study of the British
families that first identified the 7271T4G mutation and reported a
similarly large increased risk of breast cancer among three carriers
of that mutation (RR¼12.7, 95% CI 3.7–45.8) (Stankovic et al,
1998); and a second study by Broeks (Broeks et al, 2000) of early-
onset female breast cancer, where three out of the seven ATM
mutations found were IVS10-6T4G. While not all studies of ATM
gene mutations demonstrate an excess risk of breast cancer
(FitzGerald et al, 1997; Bebb et al, 1999; Shafman et al, 2000),
studies that have screened for missense mutations (Athma et al,
1996; Teraoka et al, 2001) and those that have examined risk
among family members of A-T patients (obligate heterozygotes)
(Swift et al, 1987, 1991; Pippard et al, 1988; Borresen et al, 1990;
Inskip et al, 1999; Olsen et al, 2001) have consistently found an
elevated risk. Combined, these results provide evidence for an
increased breast cancer risk associated with specific ATM gene
mutations.
Women with second primary breast cancer have an increased
genetic susceptibility to breast cancer compared to women with
unilateral breast cancer, or to the general population. Thus, any
genetic abnormality that is important in the etiology of breast
cancer will be considerably more prevalent among women who
have had a first breast primary than in the general population and,
in turn, even more common among women with bilateral breast Received 7 May 2003; revised 30 June 2003; accepted 25 July 2003
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scancer (Thompson, 1986; Begg and Berwick, 1997). So, examining
the frequency of a genetic mutation among women with bilateral
breast cancer and comparing it with the frequency among similar
women with unilateral breast cancer may provide important clues
as to its role in breast carcinogenesis.
Given the extremely high risk of breast cancer associated
with two ATM gene mutations, 7271T4G and IVS10-6T4G,
observed by Chenevix-Trench et al (2002) among multiple-case
families, the question arises concerning the role they play in
other genetically susceptible high-risk groups, including
women with multiple primary cancers. In this study, we
investigated the prevalence of these two ATM gene mutations in
a large population-based series of women with bilateral breast
cancer compared with the frequency among women with unilateral
breast cancer.
MATERIALS AND METHODS
The 1149 women included in this analysis were available from the
ongoing multicentre, population-based case–control study of
second primary breast cancer and gene–environment interactions,
the Women’s Environmental, Cancer, and Radiation Epidemiology
(WECARE) Study. The study population currently includes 511
women with asynchronous bilateral breast cancer, who serve as
cases, and 638 women with unilateral breast cancer, who serve
as controls. All participants are identified through five population-
based tumour registries (Los Angeles County Cancer Surveillance
Program, Cancer Surveillance System of the Fred Hutchinson
Cancer Research Center, State Health Registry of Iowa, Cancer
Surveillance Program of Orange County/San Diego-Imperial
Organization for Cancer Control, and the Danish Cancer Registry).
Selection is independent of a woman’s family history of cancer.
Women eligible for inclusion were under age 55 at diagnosis of the
first primary breast cancer (invasive, with localised or regional, but
not metastatic disease) and were first diagnosed between 1/1/1985
and 12/31/2000. All epidemiologic information is ascertained using
a structured telephone-administered questionnaire, and blood
samples are drawn by a study phlebotomist. The questionnaire
contains items addressing known and suspected risk factors for
breast cancer, including the family history of breast cancer and
personal demographics. Each participant provided informed
consent in accordance with the Institutional Review Board at each
study site that approved the study.
The bilateral breast cancer cases were diagnosed with contral-
ateral breast cancer (in situ or invasive, any stage) at least 1 year
after their first primary diagnosis. The second primary can be an
in situ carcinoma as women with a history of breast cancer are
more likely to be closely monitored for a second primary cancer.
All women were alive at the time of contact and had no history of
other cancers (except nonmelanoma skin cancer). For this
analysis, we selected all WECARE Study participants who had
completed their interview and donated a blood sample as of 11/10/
2002.
The ATM gene-mutation analyses were conducted using a staged
approach of initial screening by denaturing high-performance
liquid chromatography (DHPLC) followed by nucleotide sequen-
cing of exons yielding variant DHPLC profiles. DHPLC conditions
were optimised using positive controls with known mutation
status. Two independent readers scored all DHPLC and sequencing
output traces. For quality-control purposes, we randomly selected
11% of the 1149 samples (69 bilaterals and 55 unilateral) to be
rescreened, and obtained 100% agreement between the duplicate
samples. All laboratory screening was performed blinded to
sample characteristics (Bernstein et al, 2003). In all, 10 samples
with IVS10-6T4G were haplotyped with microsatellite markers
S1819 (Rotman et al, 1994), NS22 (Udar et al, 1999), S2179
(Vanagaite et al, 1995) and S1818 (Rotman et al, 1994), using
standardised alleles (Mitui et al, 2003).
RESULTS
Table 1 summarises the characteristics of the 1149 breast cancer
cases. The percent of women with a relative with breast cancer was
greater among women with two primaries compared to women
with only one (any first-degree relative: w
2¼19.74 (Po0.0001); any
second-degree relative: w
2¼4.66 (Po0.03)). This observation is
consistent with previous studies suggesting that women with
bilateral breast cancer have a genetic predisposition towards breast
cancer, and supports our hypothesis that this population may be
enriched for breast cancer susceptibility genes. Among the 1149
women in this study, the 7271T4G mutation was found in one out
of 638 (0.16%) woman with unilateral breast cancer (Table 2). The
IVS10-6T4G mutation was found in one out of 511 (0.19%)
bilateral and in eight out of 638 (1.25%) unilateral breast cancer.
Compared to women with unilateral breast cancer, the chance of
being a carrier of either mutation among the bilateral breast cancer
cases was 0.137 (95% confidence interval: 0.003–0.996). Full
screening and quality control of the other 64 coding exons of the
ATM gene was complete for seven of the 10 women. No other
mutations were detected in these samples, although two silent
polymorphisms were observed. All women with a mutation were
aged 50 or younger at diagnosis of their first primary, all had
invasive primary breast cancer, and all were Caucasian. Their
family histories were diverse and moderate; one woman reported
two affected first-degree relatives with breast cancer, three women
had one affected first-degree relative, and four subjects reported at
least one affected second-degree relative. The samples with IVS10-
6T4G were haplotyped with microsatelite markers. Although
phase was not determined, the data were compatible with the
interpretation that each sample shares a haplotype with the
homozygous IVS10-6T4G A-T patient described by Broeks et al
(2003).
Table 1 Characteristics of 1149 young women with unilateral and
bilateral breast cancer included in this study
Characteristic Bilateral (N¼511) Unilateral (N¼638)
Age at diagnosis
(mean and range)
First primary 46 (25, 54) 46 (25, 54)
Second primary 50 (28, 68) NA NA
Follow-up (years) after
diagnosis
a (mean and range)
10.8 (2.4, 17.1) 10.5 (3.6, 16.9)
Race (N and %)
White 486 95.1% 603 94.5%
Black 10 2.0 13 2.0
Asian or Pacific Islander 2 0.4 8 1.3
Native American, Aleut,
or Eskimo
3 0.6 3 0.5
Other 10 2.0 11 1.7
Family history of breast cancer
(N and %)
Any first-degree relative 161 31.5% 128 20.1%
Mother 108 21.1 86 13.5
XOne sister 76 14.9 53 8.3
XOne daughter 1 0.2 1 0.2
Any second-degree relative 148 29.0% 149 23.4%
Maternal grandmother 27 5.3 30 4.7
Paternal grandmother 25 4.9 21 3.3
XOne maternal aunt 63 12.3 70 11.0
XOne paternal aunt 54 10.6 56 8.8
aTime between first primary diagnosis and interview date.
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In the present study, we focused on the frequency of the 7271T4G
and IVS10-6T4G ATM gene mutations, because prior studies of
multiple-case families found these two mutations to be associated
with excess breast cancer. The 1149 women in our study were
population-based, and all diagnosed with a first breast cancer at a
young age (under age 51). We observed a higher prevalence of
IVS10-6T4G among unilateral breast cancer cases than bilateral
breast cancers. This frequency distribution among bilateral and
unilateral breast cancer cases is consistent with the study by
Broeks et al (2003), which also focused on early-onset breast
cancer; two out of 49 unilateral breast cancer cases and one out of
33 bilateral breast cancer cases were found to carry the IVS10-
6T4G mutation. However, in our study, the prevalence of this
mutation was more than 20-fold lower than that observed in the
Broeks study. In contrast, the family study conducted by Chenevix-
Trench et al (2002) found no IVS10-6T4G mutations in the 262
breast cancer patients who were unselected for family history; two
were observed in the 76 multiple-case breast cancer families.
Similar to our study’s 7271T4G mutation prevalence of 0.08%
(one out of 1149), Chenevix-Trench et al (2002) observed one
mutation among 525 cases and 381 controls (0.11%); all women
included in the study were under age 40. The prevalence of this
mutation was greater among the high-risk families where one out
of 76 (1.3%) carried the mutation. The 7271T4G mutation,
originally detected in a Scottish family (Stankovic et al, 1998), to
our knowledge, has only been observed in countries with a heavy
British population origin. Thus, the low prevalence of this
mutation in our study may reflect population heterogeneity.
Among the bilateral breast cancer cases, 23% were diagnosed with
an in situ second primary breast cancer; however, the single carrier
of the IVS10-6T4G with bilateral breast cancer was diagnosed
with an invasive second primary, 9.3 years after her first breast
cancer was diagnosed. Further of note, from the haplotyping data,
it appears that the IVS10-6T4G variant is carried on an ancestral
haplotype that is common to patients with both A-T and breast
cancer. This concurs with the findings of Broeks et al (2000), who
also reported that this haplotype is observed in normal individuals
carrying IVS10-6T4G and may confer incomplete penetrance.
Ancient founder ATM mutations have been associated with other
ancestral haplotypes as well (Campbell et al, 2003).
Given the likelihood that young women with bilateral breast
cancer may be carriers of inherited susceptibility alleles at loci
such as ATM, and that they are more genetically predisposed than
women with unilateral breast cancer, in our series, we would have
expected a greater frequency of germline mutations in the bilateral
group. However, the observed mutation distribution, a higher
prevalence in unilateral breast cancers than in bilateral breast
cancers, is contrary to this and to what we would have expected if
these two mutations were to play an important role in breast
carcinogenesis among such individuals at high risk. Nevertheless,
in the absence of information on the presence of any other ATM
mutations associated with breast cancer in these patients, these
results need to be interpreted cautiously.
CONCLUSION
We examined the prevalence of two ATM gene mutations among
women with unilateral and bilateral breast cancer; one out of 638
unilateral cases carried the 7271T4G mutation, while one out of
511 bilateral and eight out of 638 unilateral breast cancer cases
harboured the IVS10-6T4G mutation. Neither mutation was
associated with family history of breast cancer, age, or laterality.
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